250 related articles for article (PubMed ID: 17202811)
1. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Shi Y; He X; Yang S; Ai B; Zhang C; Huang D; Dong M; Liu P; Zhou S; Han X
Chemotherapy; 2007; 53(1):44-50. PubMed ID: 17202811
[TBL] [Abstract][Full Text] [Related]
2. [Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
Xie XD; Zheng ZD; Liu DW; Liu YY; Shan XJ
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1180-2. PubMed ID: 12921641
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
5. [Preventive effects of ramosetron and granisetron in prevention of gastrointestinal reaction associated with chemotherapeutic agents: a comparative study].
Zhang JD; Liu YP; Teng YE; Shi J
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2058-60. PubMed ID: 14703416
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
[TBL] [Abstract][Full Text] [Related]
7. Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Kim K; Chie EK; Jang JY; Kim SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
Jpn J Clin Oncol; 2009 Feb; 39(2):111-5. PubMed ID: 19060294
[TBL] [Abstract][Full Text] [Related]
8. [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
Zeng W; Zhou J; Zhang P
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):294-7. PubMed ID: 7587900
[TBL] [Abstract][Full Text] [Related]
9. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
[TBL] [Abstract][Full Text] [Related]
10. [Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
Gershanovich ML; Beresneva IA; Makhnova EV
Vopr Onkol; 2003; 49(4):505-9. PubMed ID: 14569947
[TBL] [Abstract][Full Text] [Related]
11. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
[TBL] [Abstract][Full Text] [Related]
13. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.
Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C
Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant.
Agura ED; Brown MC; Schaffer R; Donaldson G; Shen DD
Bone Marrow Transplant; 1995 Aug; 16(2):213-22. PubMed ID: 7581139
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic effect of ramosetron during hyperthermo-chemo-radiotherapy for esophageal cancer.
Morita M; Kuwano H; Ohno S; Kitamura K; Sugimachi K
Anticancer Res; 2000; 20(5C):3631-6. PubMed ID: 11268430
[TBL] [Abstract][Full Text] [Related]
16. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy of ramosetron and ondansetron in the prophylaxis of postoperative vomiting in children receiving fentanyl by patient-controlled analgesia after orthopedic surgery: a randomized controlled trial.
Park YH; Jang YE; Byon HJ; Kim JT; Kim HS
Paediatr Anaesth; 2013 Apr; 23(4):360-4. PubMed ID: 23281658
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery.
Kim SI; Kim SC; Baek YH; Ok SY; Kim SH
Br J Anaesth; 2009 Oct; 103(4):549-53. PubMed ID: 19700442
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
[TBL] [Abstract][Full Text] [Related]
20. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
